These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
302 related items for PubMed ID: 23802840
1. Long-term 4-year safety of saxagliptin in drug-naive and metformin-treated patients with Type 2 diabetes. Rosenstock J, Gross JL, Aguilar-Salinas C, Hissa M, Berglind N, Ravichandran S, Fleming D. Diabet Med; 2013 Dec; 30(12):1472-6. PubMed ID: 23802840 [Abstract] [Full Text] [Related]
2. Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus. Scheen AJ, Charpentier G, Ostgren CJ, Hellqvist A, Gause-Nilsson I. Diabetes Metab Res Rev; 2010 Oct; 26(7):540-9. PubMed ID: 20824678 [Abstract] [Full Text] [Related]
3. A randomized controlled trial of the efficacy and safety of saxagliptin as add-on therapy in patients with type 2 diabetes and inadequate glycaemic control on metformin plus a sulphonylurea. Moses RG, Kalra S, Brook D, Sockler J, Monyak J, Visvanathan J, Montanaro M, Fisher SA. Diabetes Obes Metab; 2014 May; 16(5):443-50. PubMed ID: 24205943 [Abstract] [Full Text] [Related]
4. Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial. Göke B, Gallwitz B, Eriksson J, Hellqvist A, Gause-Nilsson I, D1680C00001 Investigators. Int J Clin Pract; 2010 Nov; 64(12):1619-31. PubMed ID: 20846286 [Abstract] [Full Text] [Related]
5. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Jadzinsky M, Pfützner A, Paz-Pacheco E, Xu Z, Allen E, Chen R, CV181-039 Investigators. Diabetes Obes Metab; 2009 Jun; 11(6):611-22. PubMed ID: 19515181 [Abstract] [Full Text] [Related]
8. Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks. Pfützner A, Paz-Pacheco E, Allen E, Frederich R, Chen R, CV181039 Investigators. Diabetes Obes Metab; 2011 Jun; 13(6):567-76. PubMed ID: 21342412 [Abstract] [Full Text] [Related]
9. Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes. Mathieu C, Ranetti AE, Li D, Ekholm E, Cook W, Hirshberg B, Chen H, Hansen L, Iqbal N. Diabetes Care; 2015 Nov; 38(11):2009-17. PubMed ID: 26246458 [Abstract] [Full Text] [Related]
10. Safety and efficacy of saxagliptin added to thiazolidinedione over 76 weeks in patients with type 2 diabetes mellitus. Hollander PL, Li J, Frederich R, Allen E, Chen R, CV181013 Investigators. Diab Vasc Dis Res; 2011 Apr; 8(2):125-35. PubMed ID: 21562064 [Abstract] [Full Text] [Related]
11. Efficacy and safety of saxagliptin in drug-naïve Asian patients with type 2 diabetes mellitus: a randomized controlled trial. Pan CY, Yang W, Tou C, Gause-Nilsson I, Zhao J. Diabetes Metab Res Rev; 2012 Mar; 28(3):268-75. PubMed ID: 22081481 [Abstract] [Full Text] [Related]
12. Clinically relevant reductions in HbA1c without hypoglycaemia: results across four studies of saxagliptin. Karyekar CS, Frederich R, Ravichandran S. Int J Clin Pract; 2013 Aug; 67(8):759-67. PubMed ID: 23795975 [Abstract] [Full Text] [Related]
16. Saxagliptin: a review of its use as combination therapy in the management of type 2 diabetes mellitus in the EU. Yang LP. Drugs; 2012 Jan 22; 72(2):229-48. PubMed ID: 22221000 [Abstract] [Full Text] [Related]